Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

>2 years 16-20 visits Monitoring phase (IV)No Placebo Cost Reimbursement Partially Remote Standard Medicines InjectionRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Benlysta

Benlysta is a medicine used to treat lupus by helping reduce the immune system’s attack on the body.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Belimumab

Belimumab is a substance that reduces harmful immune activity to help treat lupus.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Centre Hospitalier Universitaire D'Angers

Internal Medicine and Clinical Immunology

Angers, France

Centre Hospitalier Universitaire De Bordeaux

Internal Medicine and infectious diseases department

Canéjan, France

Centre Hospitalier Universitaire De Lille

Internal Medicine

Loos, France

Sponsor: Glaxosmithkline Research & Development Limited

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.